Systemic TLR2 tolerance enhances central nervous system remyelination

被引:28
|
作者
Wasko, Nicholas J. [1 ]
Kulak, Meghan Home [1 ]
Paul, Debayon [1 ]
Nicaise, Alexandra M. [3 ]
Yeung, Stephen T. [1 ,5 ]
Nichols, Frank C. [4 ]
Khanna, Kamal M. [1 ,5 ]
Crocker, Stephen [3 ]
Pachter, Joel S. [1 ]
Clark, Robert B. [1 ,2 ]
机构
[1] UConn Hlth, Dept Immunol, Farmington, CT 06030 USA
[2] UConn Hlth, Dept Med, Farmington, CT 06030 USA
[3] UConn Hlth, Dept Neurosci, Farmington, CT 06030 USA
[4] UConn Hlth, Dept Periodontol, Farmington, CT 06030 USA
[5] NYU, Dept Microbiol, Langone Sch Med, Perlmutter Canc Ctr, New York, NY 10016 USA
关键词
TLR; TLR2; Tolerance; Remyelination; Multiple sclerosis; Microglia; GLIAL-CELL ACTIVATION; MICROGLIA; CNS; TOLL-LIKE-RECEPTOR-2; DIFFERENTIATION; DEMYELINATION; MACROPHAGES; CUPRIZONE; MODEL;
D O I
10.1186/s12974-019-1540-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundMultiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by both inflammatory demyelination and impaired remyelination. Studies indicate that Toll-like receptor 2 (TLR2) signaling contributes to both the inflammatory component and the defective remyelination in MS. While most MS therapeutics target adaptive immunity, we recently reported that reducing TLR2 signaling in innate immune cells by inducing TLR2 tolerance attenuates adoptively transferred experimental autoimmune encephalomyelitis. Given that previous reports suggest TLR2 signaling also inhibits myelin repair, the objective of this study was to assess how reducing TLR2 signaling through TLR2 tolerance induction affects CNS myelin repair.MethodsChow containing 0.2% cuprizone was fed to male and female wild-type (WT) C57BL/6 mice or TLR2-deficient (TLR2(-/-)) mice for 5weeks to induce demyelination. During a 2-week remyelination period following discontinuation of cuprizone, WT mice received either low dose TLR2 ligands to induce systemic TLR2 tolerance or vehicle control (VC). Remyelination was evaluated via electron microscopy and immunohistochemical analysis of microglia and oligodendrocytes in the corpus callosum. Statistical tests included 2-way ANOVA and Mann-Whitney U analyses.ResultsInducing TLR2 tolerance in WT mice during remyelination significantly enhanced myelin recovery, restoring unmyelinated axon frequency and myelin thickness to baseline levels compared to VC-treated mice. Mechanistically, enhanced remyelination in TLR2 tolerized mice was associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS(+) phenotype to a non-inflammatory/pro-repair Arg1(+) phenotype. This result was confirmed in vitro by inducing TLR2 tolerance in WT microglia cultures. TLR2(-/-) mice, without TLR2 tolerance induction, also significantly enhanced myelin recovery compared to WT mice, adding confirmation that reduced TLR2 signaling is associated with enhanced remyelination.DiscussionOur results suggest that reducing TLR2 signaling in vivo by inducing TLR2 tolerance significantly enhances myelin repair. Furthermore, the enhanced remyelination resulting from TLR2 tolerance induction is associated with a shift in corpus callosum microglia from a pro-inflammatory iNOS(+) phenotype to a non-inflammatory/pro-repair Arg1(+) phenotype. While deletion of TLR2 would be an impractical approach in vivo, reducing innate immune signaling through TLR2 tolerance induction may represent a novel, two-pronged approach for treating both inflammatory and myelin repair components of MS.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Myelin phagocytosis and remyelination of macrophage-enriched central nervous system aggregate cultures
    Copelman, CA
    Diemel, LT
    Gveric, D
    Gregson, NA
    Cuzner, ML
    JOURNAL OF NEUROSCIENCE RESEARCH, 2001, 66 (06) : 1173 - 1178
  • [42] Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination
    Lindner, Maren
    Fokuhl, Jantje
    Linsmeier, Franziska
    Trebst, Corinna
    Stangel, Martin
    NEUROSCIENCE LETTERS, 2009, 453 (02) : 120 - 125
  • [43] A unique population of circulating autoantibodies promotes central nervous system remyelination
    Asakura, K
    Rodriguez, M
    MULTIPLE SCLEROSIS, 1998, 4 (03): : 217 - 221
  • [44] The choline pathway as a strategy to promote central nervous system(CNS) remyelination
    Thomas Skripuletz
    Ralf A.Linker
    Martin Stangel
    Neural Regeneration Research, 2015, 10 (09) : 1369 - 1370
  • [45] YAP and TAZ regulate remyelination in the central nervous system
    Hong, Jiayue
    Kirkland, Julia M.
    Acheta, Jenica
    Marziali, Leandro N.
    Beck, Brianna
    Jeanette, Haley
    Bhatia, Urja
    Davis, Grace
    Herron, Jacob
    Roue, Clemence
    Abi-Ghanem, Charly
    Feltri, M. Laura
    Zuloaga, Kristen L.
    Bechler, Marie E.
    Poitelon, Yannick
    Belin, Sophie
    GLIA, 2024, 72 (01) : 156 - 166
  • [46] Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice
    Neta Lax
    Nina Fainstein
    Yossi Nishri
    Ayal Ben-Zvi
    Tamir Ben-Hur
    Journal of Neuroinflammation, 17
  • [47] Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer's disease mice
    Lax, Neta
    Fainstein, Nina
    Nishri, Yossi
    Ben-Zvi, Ayal
    Ben-Hur, Tamir
    JOURNAL OF NEUROINFLAMMATION, 2020, 17 (01)
  • [48] Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system
    Piaton, Gabriele
    Aigrot, Marie-Stephane
    Williams, Anna
    Moyon, Sarah
    Tepavcevic, Vanja
    Moutkine, Imane
    Gras, Julien
    Matho, Katherine S.
    Schmitt, Alain
    Soellner, Heidi
    Huber, Andrea B.
    Ravassard, Philippe
    Lubetzki, Catherine
    BRAIN, 2011, 134 : 1156 - 1167
  • [49] Seeing is believing: Identifying remyelination in the central nervous system
    Hill, M. F. E.
    Cunniffe, N. G.
    Franklin, R. J. M.
    CURRENT OPINION IN PHARMACOLOGY, 2022, 66
  • [50] Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination
    vanEngelen, BGM
    Pavelko, KD
    Rodriguez, M
    MULTIPLE SCLEROSIS, 1997, 3 (02): : 76 - 79